Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective safety monitoring of Ilaprazole Sodium for Injection
ChiCTR2200059300Phase 4Recruiting
- Sponsor
- Huaihe Hospital of Henan University
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ilaprazole in gastroesophageal reflux disease (GERD), Peptic ulcer disease (PUD), erosive esophagitis (EE) and 1 more, sponsored by Huaihe Hospital of Henan University. Primary endpoints: Incidence of adverse reactions and adverse events, Clinical manifestations, management, and outcomes of adverse reactions and 1 more. Started Oct 2019; status: recruiting.
02
Drugs
ilaprazole
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer disease (PUD)erosive esophagitis (EE)Acid Peptic Disease (APD)
Beyond the preview
Go deeper on ChiCTR2200059300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059300.